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Hypophosphatasia is an inherited disease characterized by reduced alkaline phosphatase activity, ex-
tracellular accumulation of inorganic pyrophosphate, and impaired bonemineralization. Asfotase alfa (AA)
is a recombinant human alkaline phosphatase therapy approved for treatment of pediatric-onset hypo-
phosphatasia. Studies show promising outcome in AA-treated children with hypophosphatasia; however,
data on adults with pediatric-onset hypophosphatasia are scarce. We report on a 59-year-old woman with
childhood-onset hypophosphatasia and a history ofmultiple fractures and orthopedic procedures. Owing to
renal failure (histological diagnosis: focal segmental glomerulosclerosis), hemodialysis was started in 2013.
By the end of 2015, the patient was unable to walk, could only stand for 30 seconds, and was completely
dependent on help for activities of daily living. After 13 months of AA therapy, the patient showed a
dramatic increase in quality of life (increased mobility), reduction in pain medication, and a significant
improvement in bonemineralization throughout the skeleton, including consolidation of existing fractures
and no occurrence of new fractures. This case report demonstrates a relevant therapeutic success of AA
treatment in an adult hemodialysis patient with childhood onset of hypophosphatasia.
Copyright © 2017 Endocrine Society
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Hypophosphatasia (HPP) is an inherited disease characterized by reduced alkaline phos-
phatase (AP) activity leading to extracellular accumulation of inorganic pyrophosphate,
which inhibits bone and tooth mineralization. It is caused by recessively or dominantly
inherited mutations within the tissue nonspecific isoenzyme of AP (TNSALP) gene on
chromosome 1p36-34 [1]. The prevalence of severe and moderate HPP in Europe has been
estimated at 1 per 300,000 and 1 per 6370, respectively [1].
As.330 mutations of the TNSALP gene have been described, patients may present with a
wide spectrum of clinical characteristics ranging from antenatal death to severe bone de-
formities in early childhood, to dental complications without bone involvement in adults. In
decreasing order of severity and according to age of onset, clinicians categorize the perinatal,
infantile, childhood, adult, and odontologic forms of HPP [1].
No approved therapy for HPP has been available until recently [2]. Asfotase alfa (AA) is a
recombinant human TNSALP combined with the constant region of human immunoglobulin
G1–Fc domain and deca-aspartate for bone targeting because it has high affinity for hy-
droxyapatite [2]. Since late 2015, treatment has been approved in Europe, Canada, and the
United States for pediatric-onset HPP. So far, studies show excellent outcomes in AA-treated
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children [2]. The necessity of a treatment option for adult HPP patients has been underlined
by a recent study revealing a substantial burden of disease in adult HPP patients [3]. Even
though approved for all childhood-onset HPP patients independent of their current age, data
about the effects of the treatment in adults are scarce.
In this report we document a 59-year-old woman with childhood-onset HPP, treated with
AA for 13 months, who responded with significant clinical and radiographic improvement.
1. Case
In summer 2009, a 51-year-old woman presented to our clinic. The diagnosis of HPP had been
made in her first year of life. She reported that early childhood development was accompanied
by feeding problems, delay in the start of walking to age 4 years after several leg surgeries,
failure to grow resulting in short stature (130 cm) (father, 173 cm;mother, 155 cm), and loss of
teeth during adolescence. Crutches for walking had been necessary continuously after left
lower leg fracture at age 26 years, followed by pseudoarthrosis of the right tibia and the left
femur in the following years. Table 1 provides an overview of the main fractures and or-
thopedic procedures during her adulthood.
Direct sequencing of exons 1 to 12 revealed homozygous TNSALP mutations in exon 5
(p.Ala116Ser) andheterozygousmutation in exon11 (p.Asn417Ser). Themutationp.Ala116Ser
is not functionally characterized; however, a p.Ala116Thr mutation results in negligible ac-
tivity [4]. The mutation p.Asn417Ser abolishes AP activity, and as a heterozygous genotype
reduces activity to ~25% [5].
At referral, she reported pain in all bones, difficulty walking, and poor quality of life. She
had received bisphosphonate therapy for a year in the past. For analgesia she was taking 43
30 drops (=3 g)/d of a nonopiod analgesia (metamizol). In addition to her HPP, she had
hypertension, hypercholesterolemia, chronic kidney disease stage 4 with renal anemia, and
nephrolithiasis, with the latter possibly related to HPP.
Owing to implant loosening in her left distal humerus and continuous pseudoarthrosis of
the right humerus, therapywith teriparatide (parathyroid hormone 1-34) was started in 2011
but withdrawn after 4 months due to proteinuria (2.6 g/L) and decreased kidney function.
Renal biopsy revealed focal segmental glomerulosclerosis (no calcium deposits). Owing to the
lack of alternative treatment options, she was given transdermal hormone replacement
therapy (0.025 mg if 17b-estradiol and 0.125 mg of norethisterone acetate) in 2013. In the
same year, hemodialysis was started.
Owing to new fractures (Table 1) and failure of prevalent fractures to heal, the patient’s
health and quality of life further deteriorated accompanied by severe bone pain. By the end of
2015, the patient could no longer walk, could only stand for 30 seconds, and was completely
dependent on help for activities of daily living and personal care.
Table 1. Main Orthopedic Events and Procedures During Adulthood in a 59-Year-Old Female With the
Childhood-Onset Form of HPP
Events and Procedures
· Fracture left lower leg 1984 (age 26 years), intramedullary nailing 1988· Pseudoarthrosis right lower leg and intramedullary nailing 1989 (age 31 years), removal 1990· External fixation right lower leg 1993 to 1994, orthosis and intramedullary nailing 2003· Pseudoarthrosis left femur and intramedullary nailing 2002· Pseudoarthrosis right humerus 2004 and intramedullary nailing July 2008· Pseudoarthrosis and fracture left humerus, plate and screw August 2009· Fracture glenoid bone left September 2010· Implant loosening left distal humerus October 2010 and open reposition and internal refixation with double plateosteosynthesis plus autologous stem cells
· Implant removal left distal humerus and neurolysis nervus ulnaris left February 2012· Orthosis left arm· Periprosthetic fracture right humerus April 2013
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At the end of 2015, AA was approved as therapy for pediatric-onset HPP in Germany.
Radiographs of arms, hands, legs, and hips were taken in January 2016 showing widespread
progressive demineralization (compared with 2013), distinct osseous deformities, and on-
going destruction of bone structure, especially of the hands (Fig. 1a and 1b, left side).
Compared with previous examinations, new radial and bilateral ulnar fractures, as well as a
new fracture around a femoral nail, were apparent. At that time, medical therapy comprised
bisoprolol (1.25 mg/d), ramipril (5 mg/d), torsemide (200 mg/d), sodium polystyrene sulfonate
(450 mg twice each week), lanthanum carbonate (750 mg/d), darbepoetin (15 mg every
2 weeks), calcium (500 mg), colecalciferol (20,000 IU every 2 weeks), and transdermal
estrogen.
Given the patient’s progressive skeletal deformity and functional impairment, treatment
was started with subcutaneous injections of 80 mg of AA three times per week (given directly
after hemodialysis) after discussion between specialists within our clinic in January 2016.
During the first 6 weeks of treatment she reported slight burning of the hands and knees and
fatigue directly after injections. Laboratory data before and during treatment are presented
in Table 2.
After 13 months of AA treatment the patient could stand and walk independently from the
wheelchair to bed (3 m). Her ability to elevate her arms was still significantly impaired, but
was clearly improved compared with January 2016. Bone pain had reduced and less pain
medication was necessary. Radiographs in February 2017 showed significantly improved
mineralization at all skeletal sites with greater improvement in the arms and hands than in
the legs, full consolidation of the radial, ulnar, and femoral fractures, and no occurrence of new
fractures (Fig. 1a and 1b, right side). Medical therapy was otherwise unchanged.
2. Discussion
No clinical trial data for adults with childhood-onset HPP treated with AA have been
published except in abstract form [6]. Data from neonates and infants with severe HPP are
available showing significantly improved survival and skeletal mineralization after AA
treatment [2, 7, 8].
In our patient with the childhood form of HPP, therapy with AA resulted in marked
improvement of mobility and pain, and only mild side effects. In addition to a significant
positive impact on her reported quality of life, bone mineralization and fracture healing
improved significantly and no new fractures occurred.
Her chronic renal failure (CRF) was attributed to hypertension, nonsteroidal anti-
inflammatory medication taken for bone pain, and chronic nephrolithiasis. Unfortunately,
we obtained no bone biopsies of our patient. However, it is likely that she had renal osteo-
dystrophy with secondary hyperparathyroidism due to CRF. This was previously shown in an
adult HPP patient with CRF requiring hemodialysis [9]. In contrast to the reported case [9],
our patient never experienced hypercalcemia after fracture. Recently, a 55-year-old manwith
odontohypophosphatasia was reported who was asymptomatic until he developed CRF,
resulting in numerous disabling fractures [10]. After successful renal transplantation, the
patient improved significantly, suggesting that renal failure might further deteriorate bone
changes in HPP. Additionally, the administration of bisphosphonate could potentially be an
additional factor in worsening of the bone disease.
In our case hemodialysis was an additional challenging point in treatment, and no ex-
perience existed regarding hemodialysis and AA treatment. Increased phosphate levels
Figure 1. X-ray images of the right hand (a) and right arm (b) in January 2016 (left side)
before asfotase therapy and in February 2017 (right side) after 13 months of asfotase therapy
in a 59-year-old female patient with the childhood-onset form of HPP.
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previously reported during AA treatment were not seen in our case, probably due to he-
modialysis. Under AA treatment we provided calcium and colecalciferol treatment.
3. Conclusion
This case report shows a significant therapeutic success of AA treatment in an adult he-
modialysis patient with the childhood form of HPP.
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